Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Feb 27;137(9):986-987.
doi: 10.1161/CIRCULATIONAHA.117.031193.

Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"

Heinrich Taegtmeyer  1 , Anja Karlstaedt  1
Affiliations
Comment

Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"

Heinrich Taegtmeyer et al. Circulation. .
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jorgensen ME, Thuresson M, Arya N, Bodegard J, Hammar N, Fenici P. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The cvd-real study 3 (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors) Circulation. 2017;136:249–259. - PMC - PubMed
    1. Taegtmeyer H, Beauloye C, Harmancey R, Hue L. Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol. 2013;305:H1693–H1697. - PMC - PubMed
    1. Khalaf KI, Taegtmeyer H. After avandia: The use of antidiabetic drugs in patients with heart failure. Tex Heart Inst J. 2012;39:174–178. - PMC - PubMed
    1. Leichman JG, Wilson EB, Scarborough T, Aguilar D, Miller CC, III, Yu S, Algahim MF, Reyes M, Moody FG, Taegtmeyer H. Dramatic reversal of derangements in muscle metabolism and diastolic left ventricular function after bariatric surgery. Am J Med. 2008;121:966–973. - PMC - PubMed
    1. Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl Med. 2017;376:2300–2302. - PubMed